ArticleRomanian journal of ophthalmology
Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- Post-Operative Outcomes at One Year of STREAMLINE Microinvasive Glaucoma Surgery Combining Micro-Goniotomy and Focal Ab-Interno Canaloplasty.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- The Association of Primary Open Angle Glaucoma and Ocular Hypertension with Anti-VEGF Injections.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections.Scientific reports · 2021Observational
- Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration.BMC ophthalmology · 2021Article
- Effects of Varying Intranasal Treatment Regimens in ST266-Mediated Retinal Ganglion Cell Neuroprotection.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2019Article
- Aflibercept Versus Bevacizumab as First-Line Therapy in Age-Related Macular Degeneration.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.